OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hepatology is 99. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement	2132
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update	1558
Baveno VII – Renewing consensus in portal hypertension	931
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update	713
COVID-19: Abnormal liver function tests	653
EASL recommendations on treatment of hepatitis C: Final update of the series☆	645
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma	578
Global burden of primary liver cancer in 2020 and predictions to 2040	446
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19	446
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study	404
COVID-19 and the liver	354
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study	351
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	332
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis	318
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials	293
COVID-19: Discovery, diagnostics and drug development	288
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology	288
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆	286
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients	276
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis	275
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma	270
High rates of 30-day mortality in patients with cirrhosis and COVID-19	257
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	252
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients	251
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials	244

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States	238
Update on NAFLD genetics: From new variants to the clinic	236
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy	223
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer	222
Systemic treatment of hepatocellular carcinoma: An EASL position paper	215
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis	208
Global burden of liver disease: 2023 update	203
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry	200
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	195
Impact of COVID-19 on global HCV elimination efforts	180
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis	176
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis	169
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis	166
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients	165
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis	165
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma	164
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis	161
Epidemiology and risk-stratification of NAFLD-associated HCC	160
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?	159
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis	157
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆	155
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology	154
Sarcopenia and frailty in decompensated cirrhosis	152
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction	152
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy	150
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits	150
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis	149
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis	148
The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care	145
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis	143
Animal models for liver disease – A practical approach for translational research	140
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	136
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping	134
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy	131
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score	129
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort	127
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry	126
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis	125
A new perspective on NAFLD: Focusing on lipid droplets	125
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases	124
Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”	122
Lytic cell death in metabolic liver disease	118
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma	118
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis	117
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options	117
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription	116
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy	116
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation	116
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?	115
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis	113

Innate immune cells in cirrhosis	113
The microbiota in cirrhosis and its role in hepatic decompensation	113
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease	112
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial	112
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	112
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma	112
Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance	112
IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease	110
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma	110
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	109
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation	108
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease	108
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension	107
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis	107
Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view	106
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS	105
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension	105
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	103
COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma	102
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma	102
Association of liver abnormalities with in-hospital mortality in patients with COVID-19	101
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma	100
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis	100
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)	99